Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06142188 | NOT YET RECRUITING | Lymphoma, B-Cell

Relmacabtagene Autoleucel in Hematologic Malignancies
Sponsor:

Shanghai Ming Ju Biotechnology Co., Ltd.

Brief Summary:

To evaluate the efficacy and safety of Relmacabtagene Autoleucel in the treatment of adult patients with hematologic malignancies in real-world

Condition or disease

Lymphoma, B-Cell

Large B-cell Lymphoma

Follicular Lymphoma

Intervention/treatment

Relmacabtagene Autoleucel

Detailed Description:

The purpose of this study is to observationally evaluate the efficacy and safety data of Relmacabtagene Autoleucel for the treatment of patients with hematologic malignancies for up to 15 years after infusion. The treating physician will determine the most appropriate diagnostic and therapeutic regimen for the patient based on clinical practice. No therapeutic intervention will be administered to patients in this study.

Study Type : OBSERVATIONAL
Estimated Enrollment : 150 participants
Official Title : A Real-world Study for the Treatment of Hematologic Malignancies With Relmacabtagene Autoleucel
Actual Study Start Date : 2023-12-28
Estimated Primary Completion Date : 2038-12-31
Estimated Study Completion Date : 2038-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • 1. Signed informed consent
  • 2. Patients who have been treated with Relma-cel, including those who have received off-label products;
  • 3. If previously enrolled in another clinical study, they must have completed follow-up in the previous study, or have withdrawn or lost follow-up in the previous study.
Exclusion Criteria
  • 1.Patients who have been treated with Relma-cel and then have been treated with other CAR-T products.
Relmacabtagene Autoleucel in Hematologic Malignancies

Location Details

NCT06142188

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

China, Beijing

Beijing Cancer Hospital

Beijing, Beijing, China, 100010

Not yet recruiting

China, Beijing

Peking University International Hospital

Beijing, Beijing, China, 100010